U
ABUS icon

UBS’s Arbutus Biopharma ABUS Stock Holding History

UBS’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$104K Buy
4,900
+4,800
+4,800% +$78.4K ﹤0.01% 5942
2014
Q2 		$1K Buy
+100
New +$1.42K ﹤0.01% 10179

Other funds holding ABUS

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
AWMDMG
Austin W. Marxe & David M. Greenhouse New York $733M AUM 21.72% 1-Year Est. Return
BG
BlackRock Group London, United Kingdom $210B AUM 15.5% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

UBS's ABUS Position: Q3 2014 in Review

UBS increased its Arbutus Biopharma (ABUS) stake by 6,467% in Q3 2014, buying an estimated $1.58M and bringing the position to 98,498 shares worth $2.08M. The position accounts for ﹤0.01% of the portfolio, ranked #2878.

UBS first reported a position in ABUS in Q3 2013 and has held it in 5 quarters since. 48 funds tracked by Wall St. Rank hold ABUS as of Q3 2014.

  • UBS held 98,498 shares of Arbutus Biopharma worth $2.08M as of Q3 2014.
  • UBS bought 96,998 Arbutus Biopharma shares in Q3 2014, an estimated $1.58M.
  • Arbutus Biopharma made up ﹤0.01% of UBS's portfolio in Q3 2014, its #2878 holding.
  • UBS first reported a position in Arbutus Biopharma in Q3 2013 and has held it in 5 quarters since.
  • 48 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.